Fernando Dangond

4.7k total citations
94 papers, 3.2k citations indexed

About

Fernando Dangond is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Fernando Dangond has authored 94 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 25 papers in Oncology and 22 papers in Genetics. Recurrent topics in Fernando Dangond's work include Multiple Sclerosis Research Studies (51 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Polyomavirus and related diseases (14 papers). Fernando Dangond is often cited by papers focused on Multiple Sclerosis Research Studies (51 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Polyomavirus and related diseases (14 papers). Fernando Dangond collaborates with scholars based in United States, Germany and Italy. Fernando Dangond's co-authors include David A. Hafler, Gavin Giovannoni, Steven G. Gray, Steven R. Gullans, Sandra Camelo, Anja Windhagen, Patrick Vermersch, Antonio Iglesias, Jia Newcombe and Stuart D. Cook and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Fernando Dangond

93 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fernando Dangond United States	26	1.3k	1.0k	809	667	614	94	3.2k
Joachim Burman Sweden	28	1.6k 1.3×	507 0.5×	686 0.8×	814 1.2×	669 1.1×	111	2.8k
Mark Wing United Kingdom	29	929 0.7×	645 0.6×	1.2k 1.4×	452 0.7×	339 0.6×	47	3.0k
Martin S. Weber Germany	41	2.6k 2.1×	967 0.9×	2.6k 3.2×	875 1.3×	1.1k 1.8×	150	5.4k
Norbert Sommer Germany	30	1.2k 0.9×	688 0.7×	1.3k 1.6×	484 0.7×	1.2k 2.0×	80	3.7k
Malek Faham United States	27	943 0.7×	1.5k 1.4×	706 0.9×	1.2k 1.8×	175 0.3×	92	4.2k
Philippe Truffinet France	18	2.0k 1.6×	290 0.3×	407 0.5×	636 1.0×	946 1.5×	68	2.6k
Masaaki Niino Japan	30	1.7k 1.4×	661 0.6×	1.3k 1.6×	426 0.6×	623 1.0×	140	3.3k
Paolo A. Muraro United Kingdom	41	3.8k 3.0×	803 0.8×	1.9k 2.4×	1.4k 2.1×	1.1k 1.7×	128	5.9k
Marco Seri Italy	38	279 0.2×	2.3k 2.2×	488 0.6×	510 0.8×	315 0.5×	193	5.3k
A Wajgt Poland	10	2.5k 2.0×	371 0.4×	872 1.1×	1.3k 1.9×	828 1.3×	37	3.3k

Countries citing papers authored by Fernando Dangond

Since Specialization

Citations

This map shows the geographic impact of Fernando Dangond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Dangond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Dangond more than expected).

Fields of papers citing papers by Fernando Dangond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Dangond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Dangond. The network helps show where Fernando Dangond may publish in the future.

Co-authorship network of co-authors of Fernando Dangond

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Dangond. A scholar is included among the top collaborators of Fernando Dangond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Dangond. Fernando Dangond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freedman, Mark S., Patricia K. Coyle, Kerstin Hellwig, et al.. (2024). Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy. 13(2). 283–322. 4 indexed citations

Stefano, Nicola De, Maria Pia Sormani, Gavin Giovannoni, et al.. (2021). Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal. 28(1). 111–120. 21 indexed citations

Giovannoni, Gavin, Gıancarlo Comı, Kottil Rammohan, et al.. (2021). Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in Therapy. 38(9). 4975–4985. 23 indexed citations

Cree, Bruce, James D. Bowen, Hans‐Peter Hartung, et al.. (2020). Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders. 49. 102695–102695. 8 indexed citations

Freedman, Mark S., Staley A. Brod, B. Singer, et al.. (2019). Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. Journal of Neurology. 267(1). 64–75. 4 indexed citations

Stüve, Olaf, Thomas Leist, Gavin Giovannoni, et al.. (2019). Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders. 12. 1278076554–1278076554. 79 indexed citations

Giovannoni, Gavin, Per Soelberg Sørensen, Stuart D. Cook, et al.. (2017). Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal. 24(12). 1594–1604. 243 indexed citations

Stefano, Nicola De, Antonio Giorgio, Marco Battaglini, et al.. (2017). Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal. 24(2). 222–226. 48 indexed citations

Giovannoni, Gavin, Kottil Rammohan, Stuart D. Cook, et al.. (2017). Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351). Neurology. 88(16_supplement). 2 indexed citations

10.

Comi, Giancarlo, Thomas Leist, Mark S. Freedman, et al.. (2017). Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) (P6.349). Neurology. 88(16_supplement). 2 indexed citations

11.

Stefano, Nicola De, Antonio Giorgio, Marco Battaglini, et al.. (2016). Cladribine effect on brain volume loss and its correlation with disability progression in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal. 22. 216–216. 1 indexed citations

12.

Cook, Stuart D., Kottil Rammohan, Peter Rieckmann, et al.. (2016). Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058). Neurology. 86(16_supplement). 2 indexed citations

13.

Iglesias, Antonio, et al.. (2006). Histone deacetylase 3 represses HTLV-1 tax transcription. Oncology Reports. 16(3). 581–5. 12 indexed citations

14.

Gray, Steven G., Antonio Iglesias, Fernando Lizcano, et al.. (2005). Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein. Journal of Biological Chemistry. 280(31). 28507–28518. 115 indexed citations

15.

Ryu, Hoon, Karen Smith, Sandra Camelo, et al.. (2005). Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry. 93(5). 1087–1098. 290 indexed citations

16.

Camelo, Sandra, Antonio Iglesias, Daehee Hwang, et al.. (2005). Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 164(1-2). 10–21. 230 indexed citations

17.

Dangond, Fernando. (2002). Disorders of myelin in the central and peripheral nervous systems. Butterworth-Heinemann eBooks. 8 indexed citations

18.

Dangond, Fernando, et al.. (1999). Cloning and Expression of a Murine Histone Deacetylase 3 (mHdac3) cDNA and Mapping to a Region of Conserved Synteny between Murine Chromosome 18 and Human Chromosome 5. PubMed. 2(2). 91–96. 8 indexed citations

19.

Dangond, Fernando, David A. Hafler, Jeffrey K. Tong, et al.. (1998). Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells. Biochemical and Biophysical Research Communications. 242(3). 648–652. 96 indexed citations

20.

Mikati, Mohamad A., Helen Maguire, Charles F. Barlow, et al.. (1992). A syndrome of autosomal dominant alternating hemiplegia. Neurology. 42(12). 2251–2251. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact